Filtered By:
Specialty: Cardiology

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 800 results found since Jan 2013.

Synthesis of siRNA nanoparticles to silence plaque-destabilizing gene in atherosclerotic lesional macrophages
Nat Protoc. 2022 Feb 4. doi: 10.1038/s41596-021-00665-4. Online ahead of print.ABSTRACTMacrophages in atherosclerotic lesions promote plaque progression and are an attractive therapeutic target in cardiovascular research. Here we present a protocol for synthesis of small interfering RNA (siRNA) nanoparticles (NP) that target lesional macrophages as a potential treatment for atherosclerosis. Ca2+/calmodulin-dependent protein kinase γ (CaMKIIγ) activity in macrophages of advanced human and mouse atherosclerotic plaques drives necrosis by downregulating the expression of the efferocytosis receptor MerTK. Therefore, selectiv...
Source: Atherosclerosis - February 5, 2022 Category: Cardiology Authors: Xiangang Huang Chuang Liu Na Kong Yufen Xiao Arif Yurdagul Ira Tabas Wei Tao Source Type: research

VCAM-1-binding peptide targeted cationic liposomes containing NLRP3 siRNA to modulate LDL transcytosis as a novel therapy for experimental atherosclerosis
CONCLUSION: These findings established a novel strategy for targeting the NLRP3 inflammasome using NLRP3 siRNA-PCLs to interrupt LDL transcytosis, representing a potential novel therapy for atherosclerosis.PMID:35917895 | DOI:10.1016/j.metabol.2022.155274
Source: Atherosclerosis - August 2, 2022 Category: Cardiology Authors: Xiong Jia Xiangli Bai Xiaoyan Yang Ling Wang Yajing Lu Lin Zhu Ying Zhao Wenzhuo Cheng Meng Shu Qiyong Mei Si Jin Source Type: research

Anti-HB-EGF Antibody-Mediated Delivery of siRNA to Atherosclerotic Lesions in Mice.
Authors: Tsuchida S, Matsuzaki T, Yamato M, Okuda K, Fu HY, Araki R, Sanada S, Asanuma H, Asano Y, Asakura M, Hao H, Takashima S, Kitakaze M, Sakata Y, Mekada E, Minamino T Abstract For atherosclerotic cardiovascular diseases (ACD), gene therapy may be a potential therapeutic strategy; however, lack of effective and safe methods for gene delivery to atherosclerotic plaques have limited its potential therapeutic applications. To overcome this limitation, we developed a novel antibody-based gene delivery system (anti-HB-EGF/NA vector) by chemically crosslinking antibodies against human heparin-binding epidermal growt...
Source: International Heart Journal - November 7, 2018 Category: Cardiology Tags: Int Heart J Source Type: research

Recombinant Adenovirus siRNA Knocking Down the Ndufs4 Gene Alleviates Myocardial Apoptosis Induced by Oxidative Stress Injury
In conclusion, we successfully constructed Ndufs4 siRNA recombinant adenovirus; furthermore, the downexpression of the Ndufs4 gene may alleviate H2O2-induced H9c2 cell apoptosis.PMID:36741296 | PMC:PMC9897913 | DOI:10.1155/2023/8141129
Source: Cardiology Research and Practice - February 6, 2023 Category: Cardiology Authors: Beibei Wang Jinsheng Zhang Aijun Xu Source Type: research

Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Pre-Specified Secondary End Points in ORION 1.
Conclusions -Inclisiran produces significant and prolonged reductions in atherogenic lipoproteins, suggesting that inhibiting synthesis of PCSK9 through siRNA may be a viable alternative to other approaches which target PCSK9. Clinical Trial Registration -URL: https://www.clinicaltrials.gov. Unique identifier: NCT02597127. PMID: 29735484 [PubMed - as supplied by publisher]
Source: Circulation - May 7, 2018 Category: Cardiology Authors: Ray KK, Stoekenbroek RM, Kallend D, Leiter LA, Landmesser U, Wright RS, Wijngaard P, Kastelein JJ Tags: Circulation Source Type: research

Delivery of siRNA to Endothelial Cells In Vivo Using Lysine/Histidine Oligopeptide-Modified Poly( β -amino ester) Nanoparticles
ConclusionsWe demonstrate that C6-KH pBAE can used for delivery of siRNAs to the artery endothelium and lung, while minimizing potential side or toxic effects in the liver and heart.
Source: Cardiovascular Engineering and Technology - January 20, 2021 Category: Cardiology Source Type: research

Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran)
AbstractPurpose of ReviewThe aim of low-density lipoprotein-cholesterol (LDL-C) lowering therapies is to safely achieve a consistent and long-term reduction in exposure of the vasculature to atherogenic lipoproteins in order to reduce the risk of atherosclerotic cardiovascular (CV) disease and the associated CV events, such as myocardial infarctions and ischemic strokes. This review summarizes the concept and clinical development of a novel molecular approach to efficiently lower LDL-C, a synthetic small interfering ribonucleic acid (siRNA) —inclisiran—directed against proprotein convertase subtilisin-kexin type 9 (PCS...
Source: Current Cardiology Reports - October 21, 2020 Category: Cardiology Source Type: research

Polyethyieneimine siRNA complexes released from coated electrospun polyethylene terephthalate bypass graft materials facilitate gene silencing in infiltrating primary human aortic smooth muscle cells
Anastomotic intimal hyperplasia (AIH) remains the leading cause of prosthetic arterial graft failure. Use of electrospun PET (ePET) can be an alternative to conventional PET grafts. RNAi is a promising tool to silence genes contributing to AIH, including thrombospondin-2 (TSP-2) previously shown by us to be up-regulated in AIH. Delivery of silencing RNA (siRNA) from ePET graft to the anastomotic sites could potentially mitigate AIH.
Source: Cardiovascular Pathology - May 1, 2013 Category: Cardiology Authors: Christoph S. Nabzdyk, Maggie Chun, Hunter Oliver-Allen, Matthew D. Phaneuf, Saif G. Pathan, Jin-Oh You, Leena Pradhan, Frank W. LoGerfo Tags: Available Online Only: Meeting Abstracts Source Type: research

Dyslipidaemia: Promising results with siRNA against PCSK9
Nature Reviews Cardiology 14, 252 (2017). doi:10.1038/nrcardio.2017.43 Author: Irene Fernández-Ruiz Two single injections of inclisiran, a small interfering RNA (siRNA) that targets PCSK9 mRNA, induce a 50% reduction in LDL-cholesterol (LDL-C) levels in 6 months, according to findings from the phase II ORION-1 trial presented at ACC.17. A total of 501 patients at high
Source: Nature Reviews Cardiology - March 31, 2017 Category: Cardiology Authors: Irene Fern ández-Ruiz Tags: Research Highlight Source Type: research